Enthusiasts, entrepreneurs, and the curious about industries involved with crypto, arts, music, tech, esports, and more are all invited to attend NFT Expoverse. This event will be held in Los Angeles, California from the July 29-31, 2022. While 2021 proved a turning point for the blockchain space, interest in blockchain technologies and NFTs seem to be increasing even more rapidly in 2022, making it a perfect year for an event like NFT Expoverse. The city of Los Angeles is perfect for this conference as it’s a historical melting point of culture, technology, and recreation. The event will gather some of the industry’s most sought-out speakers, all of whom will share their insights obtained from their own personal experiences in the field. Attendees will come out as experts themselves by the end of the event! All of NFT Expoverse’s participants can learn, connect with peers, seek guidance, build long-term business ties with their mentors, and conduct business with top-rated brands. This event is the complete package for enthusiasts and beginners, allowing them to dive into all things web3, cryptocurrency, NFT markets, and metaverse experiences. Blockchain technologies are opening up a world of possibilities, among them the ability to mint what is known as NFTs (Non-fungible tokens). These blockchain based tokens represent unique digital assets like art, music, videos, and gaming items. NFTs are encrypted with the creator’s signature and use blockchain software to verify the ownership and originality of the assets. That being said, tons of creators from around the globe are now preparing for an exciting opportunity to elevate their careers at NFT Expoverse. Brands can leverage NFT Expoverse’s opportunities by bringing their products and services to the forefront as exhibitors throughout the event. This will allow them to connect with potential investors and engage with the audience in real life. “NFT Expoverse gives everyone the chance to connect in person, ask their questions in real-time, and take part in experiences they won’t be able to have over a Zoom. This event is extremely unique as it caters to attendees like my parents (the curious) all the way to those already established in this industry (the creators) and everyone in between.” Nicole Beiner, Marketing Director of NFT Expoverse. The team behind NFT Expoverse wants to ensure a one-of-a-kind experience by having unique immersive experiences, an NFT art gallery, VIP experiences, and much more. Additionally, this event is being held by a company called ZJ Events, which has an extensive background in creating unique trade show experiences in alternative industries. Those who purchase their tickets early on will get access to special offers. Plus, they have partnered with several hotels nearby the venue to make your visit even smoother. Attendees will have access to refreshments and a networking break, in addition to speaking sessions and hundreds of exhibits. The icing on the cake is that after the immersive sessions are over, participants can enjoy NFT Expoverse’s official after party! To get tickets, please visit https://nftexpoverse.com.

• Flora’s 2021 acquisitions allowed it to expand its operations beyond North America and into Europe
• Acquisitions have also contributed to 450% YOY revenue growth for Q1 2022
• Its management is confident that the foundation laid down so far will yield growth for 2022 and subsequent financial years
• Flora has also reiterated 2022 revenue guidance of $35 million to $45 million

2021 was an excellent year for Flora Growth (NASDAQ: FLGC). According to a recent research report from Zacks (https://ibn.fm/xnXve), the company possesses a number of important qualities pointing to continued significant growth following a strong 2021. Flora Growth management even regarded the past year as “transformational,” particularly following the closing of supplier, vendor, and distribution agreements that would see the company expand its operations, market reach, and product line. With the progress made by the company so far, it is looking to benefit from a first-mover advantage in multiple market categories in terms of increased value for its shareholders, a higher market share, and increased revenue going forward. The report went on to talk about 2021’s acquisition of Vessel Brand, Inc., a move that allowed the company to establish a foothold in the United States cannabis accessories business while improving its e-commerce capabilities. The year would also see the construction of an all-outdoor cultivation and on-site extraction facility in Colombia, one of the largest traditional flower exporters in the world and now able to export cannabis flowers. Such moves position Flora to take advantage of the potential of the marijuana industry, particularly the medical marijuana sector. According to a report from Grand View Research, the global medical marijuana market size was valued at USD 11.0 billion in 2021 and is projected to expand at a compound annual growth rate (“CAGR”) of 21.6% from 2022 to 2030 (https://ibn.fm/orzCj). Through its acquisitions, Flora has expanded its operations beyond North America and into Europe. The company’s investment in Hoshi International, for instance, opened it to the European Union (“EU”), allowing it to expand its global footprint that would further spread to Hong Kong, Latin America, and Israel. The report also pointed out Flora’s Life Sciences pillar, one of its three key pillars of growth, focused on providing scientific-based research associated with cannabis. The other two pillars include Commercial and Wholesale and House of Brands. The company believes that, while offering the products in its portfolio is critical, educating consumers and potential customers is of the essence if the conversation around cannabis is to be advanced. Therefore, Flora remains committed to creating educational platforms and conducting research studies and clinical trials to develop plant-based, medical-grade pharmaceuticals, phytotherapeutics, and dietary supplements. Through its acquisitions and growing distribution network, Flora was able to post a 450% year-over-year revenue growth for the first quarter of the 2022 financial year. As a result, its management is confident that, for the entire fiscal year, the company will post between $35 million and $45 million in revenue. This will be significantly influenced by the JustCBD acquisition, the awarding of an export quota for 43.6 tons of high-THC cannabis in Colombia, and the successful completion of the requisite steps to allow for the commercial planting and export of psychoactive cannabis. Flora looks to reach cash flow breakeven as revenue continues to ramp, having closed the 2021 fiscal year with about $37.6 million in cash and a $21.4 million loss. 2021 was its first full year of revenue. Still, the company anticipates accelerating revenue growth in 2022 as it activates its Wholesale and Life Sciences growth units while simultaneously fueling expansion in the global House of Brands. Flora is aggressively pushing its brand and advancing the conversation around cannabis. In addition, with its able management, Flora is recognizing and capitalizing on opportunities that others are yet to identify, placing it in a unique position that not only gives it a first-mover advantage, but also presents a unique opportunity for growth. The full Zacks Small-Cap Research Report is available at https://ibn.fm/xnXve. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The Lightning Network capacity is US $82,800,210
• LQwD’s longest running node is US-West, with a capacity of 5.74404405 BTC/ 574,404,405 sat/ US $117,517.28, a channel count of 107, and a node count of 106
• LQwD has a total of 17 active nodes worldwide on the Lightning Network
• The global cryptocurrency market was valued at US $1.49 billion and is expected to reach US $4.94 billion by 2030

Five years ago, on May 10, 2017, Christian Decker of Blockstream made the first non-test transaction on the Lightning Network. The transaction, conducted in Litecoin, was settled within one second. Today, the Lightning Network has grown on a massive scale, with over 17,000 nodes and almost 85,000 channels. The Network’s capacity, as of June 23, 2022, was US $82,800,210. LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption, has invested its own reserves in enhancing the experience of the Lightning Network. In November 2021, LQwD launched its first node and proprietary platform as a service offering (“PaaS”), https://lqwd.tech/, to the public. As LQwD’s longest operational node, US-West has a capacity of 5.74404405 BTC/ 574,404,405 sat/ US $117,517.28, a channel count of 107, and a node count of 106. A satoshi (“sat”) is the smallest measurable unit of BTC, equal to 0.00000001 BTC, and is named after Bitcoin creator Satoshi Nakamoto. Since the initial launch of the US-West node, the company has released 16 other nodes worldwide. In addition to US-West, LQwD’s presence on the Lightning Network includes Hong Kong, Ireland, India, Germany, Brazil, Singapore, Sweden, South Korea, South Africa, Bahrain, Indonesia, Italy, France, Canada, England, and Japan. Collectively, LQwD’s nodes range in size with channel counts spanning 2 (newer nodes) to 107 (US-West). To learn more about the Lightning Network and LQwD’s node operations, visit www.1ml.com. The blockchain infrastructure cannot facilitate fast transaction speeds on its own. Currently, the infrastructure can only accommodate seven transactions per second (“TPS”). Other cryptocurrencies offer a TPS ranging from 20 to 4,000, with major network Visa handling up to 24,000 TPS. As a layer 2 protocol, the Lightning Network can speed up transaction times, offering over one million TPS. LQwD is leveraging this technological advantage to drive bitcoin adoption and facilitate transactions worldwide. In its mission to accelerate bitcoin adoption, LQwD, through subsidiary Coincurve.com, joined Visa’s (NYSE: V) Fintech Fast Track Program. According to Shone Anstey, LQwD CEO, “Our direct relationship with Visa now gives LQwD the advantage of accessing their growing partner network, as well as experts in the payments space. It’s a big benefit” (https://ibn.fm/036g2). Driving bitcoin adoption is critical on a fast-growing global cryptocurrency market, despite recent volatility in the space. In 2020, the global cryptocurrency market was valued at US $1.49 billion. By 2030, this market is expected to reach US $4.94 billion, growing at a CAGR of 12.8%. Driving factors for growth include the increased need for operational efficiency, transparency in financial payment systems, the demand for remittances in developing countries, increased data security, and improved market cap (https://nnw.fm/d5wBo). (https://ibn.fm/FPE75). El Salvador was the first country to convert its legal tender to cryptocurrency. Other countries have expressed an interest in doing so, but few have made the official move. Unlike fiat currency, cryptocurrency is not asset-backed (or government-backed), making it more volatile than the standard dollar bill. Fiat currency has its volatility, too. As the government economic factors shifts, so does the value of the dollar. Once worth its weight in gold, the dollar faced devaluation when President Nixon ended the conversion for gold in the 1970s, proving that even the most stable payment systems can sometimes become volatile (https://ibn.fm/F60sB). For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Global EV market projected to see 24.5% CAGR between 2022 and 2028
• MULN announces plans to modify high-voltage plant to produce packs used for company’s EVs
• Company anticipates using its own revolutionary solid-state battery technology in its second-generation Mullen FIVE EV Crossovers
• Strategic move reduces company’s reliance on third-party suppliers, reduces impact of supply and critical component shortages

Amid a growing global demand for electric vehicles (“EV”), smart companies operating in the space are looking for ways to differentiate themselves from the competition. That’s exactly what Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle manufacturer, has done with its recently announced plans to retrofit a high-voltage facility for production of EV battery packs to support its growing line of electric vehicles (https://ibn.fm/PqP6H). The company expects to also eventually begin the development of solid-state polymer battery packs, which will be a significant advancement over current lithium-ion battery packs (https://ibn.fm/ZdV37). According to a recent Facts & Figures report, the “global electric vehicle (‘EV’) market size is estimated to cross USD $980 billion by 2028, at a CAGR of 24.5% between 2022 and 2028” (https://ibn.fm/VEK4I). The report, which looked at a variety of different factors and their projected impact on EV market growth, noted that “a variety of batteries are used in these vehicles. “The electric vehicle was developed primarily to replace polluting traditional ways of transportation,” the report continued. “As a result of various technological developments, it has gained in popularity. [An EV] outperforms traditional automobiles in terms of fuel efficiency, carbon emissions, and maintenance, as well as ease of charging at home, a smoother ride, and less engine noise. Pure, hybrid, and plug-in hybrid batteries are the three primary types of electric car batteries.” Mullen, an emerging electric vehicle manufacturer, recently announced that it plans to begin EV battery-pack production in its California-based high-voltage-battery research-and-development facility. In order to do so, the company is modifying an existing facility to house production of EV battery packs, which will be used in the company’s EVs, including the ONE EV Cargo Van, FIVE EV Crossover and DragonFLY EV Sportscar. “Building our own battery packs makes sense as it reduces our reliance on third-party suppliers and lessens our risk of being subjected to the waves of supply and critical component shortages,” said Mullen CEO and chair David Michery. “The entire industry is struggling with supply chain issues, and the more control we have in-house, the better off our vehicle programs will be. Our Monrovia facility is already established for high-voltage applications, so retrofitting it for our battery-pack development makes good sense for our company and shareholders.” In addition to reducing third-party dependency, the move to bring battery-pack production in-house will lower costs and increase overall quality control, Michery noted. For almost a decade, the facility was used for battery-pack research, development and production for CODA Automotive; Mullen purchased the assets from CODA in 2014 and took over plant production in 2017. The move to focus on battery production for Mullen-specific EVs makes sense as the company continues to expand its vehicle portfolio. In addition, the company is testing its own solid-state polymer battery technology, which has the potential to deliver more than 600-plus miles of range and features an 18-minute DC fast charge that can yield more than 300 miles of range. The company anticipates using this new battery technology in its second-generation Mullen FIVE EV Crossovers (https://ibn.fm/62cfG). According to the company, since its first quarter as a public company in 2021, Mullen has debuted two versions of the Mullen FIVE show cars, as well as continuing to focus on its development portfolio. The company also purchased a facility in Tunica, Mississippi, where it plans to start with the manufacturing of the Mullen ONE EV Cargo van program, which is slated for availability in Q2 2022. The company is capturing attention with its lineup of vehicles. The Mullen FIVE was named Top Zero Emission SUV as part of the ZEVA Awards at the Los Angeles International Auto Show in November 2021, and the company has filed more than 120 patents in 24 countries related to the vehicle. Mullen is a Southern California–based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• Aditxt, Inc. is a is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The Company’s product AditxtScore(TM) is a proprietary immune mapping technology designed to provide a personalized profile of the immune system; AditxtScore(TM) for COVID-19 is the Aditxt’s first commercial product
• Aditxt recently announced it had authorized a new channel partner – Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab –to offer AditxtScore(TM)
• This announcement comes amid reports warning of a fall and winter COVID-19 wave occasioned by waning immunity or a possible “nasty new variant”
• Already, the U.S. is undergoing a sixth wave even before the start of the summer

During the one week to May 18, the U.S. averaged roughly 100,000 COVID-19 cases each day, representing an increase of more than 3x from the lowest figure reported in March, yet the numbers did not include at-home test results, according to a Washington Post article. The piece quotes experts’ assumptions that the infections in their communities are five to ten times the official counts (https://ibn.fm/QgkXo). Despite the disparity in the reported figures, the sheer number of infections is still a cause for concern, with White House health officials urging Americans to stay up-to-date with vaccines and booster shots, get tested, and wear masks. And as the country ushers in the summer season, experts are quick to sound alarm bells, warning that this summer’s surge in COVID-19 cases could be worse than last year’s because the May 2022 cases were considerably higher than they were a year earlier. “Federal officials have also warned of a possible fall and winter wave that could result in 100 million coronavirus infections driven by omicron subvariants that have shown a remarkable ability to escape immunity,” the article reads. Christopher Murray, Director of the Institute for Health Metrics and Evaluation, told the Washington Post that the anticipated spike in COVID-19 cases this fall and winter could be the result of a substantial dip in immunity or “some nasty new variant.” Already, the U.S. is undergoing a sixth wave even before the start of the summer (https://ibn.fm/wkCPJ). The immunity’s role in keeping SARS-CoV-2 – the virus that causes the COVID-19 disease – at bay has been recognized and appreciated by many experts and companies, one of which is Aditxt (NASDAQ: ADTX). Aditxt provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them. This product can be used routinely to establish changes in immune response over time (immunity trends) and provide information crucial to understanding the virus, especially amid reports of a possible fall and winter wave. The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies. Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are a result of vaccination or an immune response to a virus; whether the immune response is likely to protect against future infection; and the possible ways to minimize the risk of a future infection. The benefits of AditxtScore(TM) will now be felt by an even larger population following a recent announcement that Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab, has added this product to its list of testing services. Under the terms of this arrangement, PMLS is an authorized channel partner that will offer AditxtScore(TM) (https://ibn.fm/MvMdX). “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” commented Kevin Murdock, CEO of PMLS. “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.” PMLS joins a list of channel partners that includes the Great Lakes Medical Laboratory, Inc., The Health Watchers, Physicians Stat Lab, Sphere Dx Laboratory, and HealthBar. These partners collect and ship samples to the AditxtScore(TM) Center, Aditxt’s high complexity CLIA-certified, CAP-accredited lab, where the specimens are prepped and profiled by a team of lab scientists trained at prestigious institutions. According to the company, the results are usually readied within 48 hours of specimens’ receipt (https://ibn.fm/F3BYU).

• This program seeks to develop revenue generation for commercial real estate owners, affording them new revenue and rent opportunities using their existing energy assets
• The program will involve portfolio health assessment, design, development, and implementation of turnkey clean electrification solutions for clients
• Correlate and Abundant IoT seek to reduce friction between property owners and service providers, allowing them to meet their ESG goals

On June 21, 2022, Correlate Infrastructure Partners (OTCQB: CIPI) announced the official launch of its Correlate Portfolio Health Program, unveiled at the Channel Partner Conference and Expo that ran from April 11-14 in Las Vegas. The program, which will be executed in partnership with Abundant IoT, seeks to develop a revenue generation program for commercial real estate owners, thereby affording them new revenue and rent opportunities from their current energy assets (https://ibn.fm/URl9q). “The path to full decarbonization will take ambition and intentional execution,” noted Todd Michaels, Correlate’s Chief Executive Officer (“CEO”). “By teaming up with industry innovators and experts, we can guide commercial real estate owners in creating new revenue and rent opportunities from their existing energy assets,” he added. Abundant IoT provides worldwide technology aggregation services focused on the Internet of Things (“IoT”) and energy services. Since January 2022, this enterprise has identified and referred to Correlate over 50 commercial facilities with projected development revenue of approximately $10 million. Correlate is still in the process of pursuing and negotiating with the property owners. Together, Abundant IoT and Correlate seek to reduce friction between property owners and service providers, thereby improving their net operating income while allowing them to meet environmental, social, and governance (“ESG”) goals. In addition, these two enterprises recognize the opportunities in IoT and decarbonization. They are working towards tapping into this opportunity to bring their services closer to consumers. “According to Transforma Insights research, the global IoT market is set to grow to 24.1 billion devices in 2030, generating $1.5 trillion in annual revenue,” noted Vince Bradley, the founder of Abundant IoT. “The time is now for IoT and decarbonization solutions in the channel,” he added. The Portfolio Health program will start with a portfolio health assessment. Once completed, Correlate and Abundant IoT will design, develop, and manage the implementation of turnkey clean electrification solutions focused on locally sited solar, energy storage, electric vehicle (“EV”) infrastructure, and intelligent efficiency measures. Ultimately, the objective is to enable commercial real estate owners to benefit from the global transition to clean energy without getting into the energy business. Through this program, entrepreneurs and real estate owners can start capturing new revenue and offering enhanced tenant benefits while simultaneously increasing the overall value of their commercial real estate portfolios. The launch of this program comes in the wake of the rise in remote work, increased corporate decarbonization commitments, and growing investor demands for ESG standards. This has forced the commercial real estate sector to adjust, making the Correlate Portfolio Health Program ideal for generating long-term value for tenants, investors, communities, and employees. “Cloud proliferation coupled with the pandemic has created the ideal market opportunity for a new channel model built around IoT. Combining energy, mobility, and connectivity with the devices is a very powerful go-to-market package for customers,” noted Mr. Bradley. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Company has a two-decade history of being a “virus killer”
• Studies show Kronos filter technology reduces airborne particulate matter levels and captures respiratory viruses, resulting in 99.99% reduced exposure
• Kronos has evolved into a next-generation wellness company offering an array of air purifiers and other products to serve the indoor-air-quality market

With a long history of being a “virus killer” that stretches back almost two decades, Kronos Advanced Technologies (OTC: KNOS) has strengthened its reputation through the years for changing the way indoor air is filtered and disinfected. Today, the company offers an array of patented air purifiers for both home and office featuring the company’s proprietary technology, which fully removes harmful allergens, bacteria, viruses (including the flu), and even gases from breathing space (https://ibn.fm/gOjOA). “The company didn’t intend to cash in on the threat of a flu pandemic,” reported a November 2005 BusinessWeek article titled “Prevent a Pandemic, Make a Profit” (https://ibn.fm/TrjQO). The article noted that Kronos Advanced Technologies originally wanted to make a fan with no moving parts. “The secret: put high voltage across an array of wires,” the article stated. “That creates a flow of charged particles — ions — strong enough to pull air along. Early tests, though, showed an unexpected benefit: The electrical field also rips molecules apart, destroying pathogens such as anthrax spores or flu viruses. Of course, this feature wasn’t a big selling point in those pre-September 11 days. ‘When we said “anthrax,” people gave a yawn,’” recalled the CEO. “They aren’t so bored now,” the article continued. “Kronos’ virus killer ‘could be a hell of a device’ for filtering air everywhere from hospitals to airplanes, says Peter Goelz, former managing director of the National Transportation Safety Board.” Kronos began to talk with Korean Air and Singapore Airlines, two companies majorly affected by the Asian SARS epidemic of 2003. “We can’t keep up with the calls,” said the CEO. Only three years after BusinessWeek talked up the company, Kronos presented a paper at the Electrostatics Society of America (“ESA”) annual meeting reporting that during a two-week study of Kronos air purifiers, which were installed in a pediatric waiting room, airborne particulate matter (“PM”) samples were collected. Analysis of the PM trapped by the Kronos filters indicated reduced airborne PM levels and captured respiratory viruses, resulting in reduced exposure to airborne respiratory viruses for the waiting room occupants. The paper went on to cite other examples of the effectiveness of the Kronos technology, presenting “experimental results demonstrating high efficacy of Kronos-based air purifiers in capturing and destruction of various types of microorganisms in different environmental settings” (https://ibn.fm/mCgBF). Kronos Advanced Technologies clearly has established both a precedent and pattern of creating clean, safe air quality. The company continues that commitment today as it has evolved into a next-generation wellness company that offers an array of air purifiers and other products designed to serve the indoor-air-quality market. The company’s proprietary technology features state-of-the-art, high-voltage patented processes without the use of traditional porous HEPA filters to move air silently and filter, sterilize and purify the air while dramatically reducing energy consumption. KNOS recently acquired an 85,000-square-foot West Virginia manufacturing campus that will be retrofitted to produce advanced, proprietary air-purification devices and other wellness products (https://ibn.fm/Vvi6u). The company’s products feature unique filterless technology, with zero maintenance costs because no HEPA filters must be replaced. For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

• Nowigence’s Pluaris app can instantaneously distill knowledge buried in narrative-intensive documents from both public and private sources
• Pluaris case studies illustrate different ways innovative platform can be used
• Nowigence is focused on simplifying the challenges of learning, with so much information available today

Nowigence (OTCQB: NOWG)’s Pluaris(TM) — a comprehensive, ready-to-use artificial intelligence (“AI”) platform — is designed to build intelligence quickly. The cloud-based, knowledge-management tool supports users who are looking to advance their competence and competitiveness by gathering key information that can accelerate the pace of problem solving and decision making. According to the company, Pluaris “mimics the way that we, as humans, read, analyze, and comprehend textual data. Many of us have a backlog of work related to reading, or face issues with staying focused on the task of reading or recalling the content that we just read. Individuals, teams, and enterprises can now quickly distill knowledge 24/7 buried in narrative-intensive documents instantaneously from various data sources, both public and private.” For instance, Nowigence shares the example of one Pluaris user who received a report of a high fasting blood sugar level during a recent physical (https://ibn.fm/63g4d). His doctor suggested medication, but the user wanted to explore natural-cure remedies. “He uploaded a few research reports into Pluaris, scanned summaries, and explored the annotated labels,” the company reported. “Based on that analysis, he quickly set up Pluaris to auto-monitor topics such as ‘lowering fasting blood sugar’ and ‘low glycemic food.’ From those results, and within 10 days, he built an action list of daily habits for diet and fitness. Within two months, he brought his fasting blood sugar level back down.” In fact, the user was so impressed with the way Pluaris worked that he decided to set up a new company powered by the new platform. His company will allow individuals to auto-track and discover knowledge related to their own health, not only saving time but also gathering information that will help them make key decisions about the best course of action for their health. Another company that uses Pluaris, Tech Mahindra, employs the platform to pool data for its strategic prospects. Pluaris “integrates their existing marketing platform, customer relationship management (‘CRM’) and web-scrapes competitive sites to build a knowledge management platform for their sales, marketing, and corporate communication teams,” reports Nowigence. “Pluaris extracts key points from multiple sources and generates an annotated feed that systematically classifies and links text data from multiple files. It assists users to create hypercontextual briefings, reduce internal meetings, make quicker decisions and build deeper relations with clients.” Pluaris is a proprietary, easy-to-use platform that assists users with reading and analysis of textual data (https://ibn.fm/lMDDL). The platform generates an annotated data feed based on specified topics of interest and then automatically creates a permanent personal knowledge base from a user’s feed and private uploads. The app has human-like capabilities for comprehending textual data and providing concise summaries and precise answers to questions, while also analyzing different data perspectives, discovering new connections, creating organized nested notes and allowing teams to work together by sharing in real time from anywhere in the world. Nowigence is focused on simplifying the challenges of learning. By integrating state-of-the-art data-processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to NOWG are available in the company’s newsroom at https://ibn.fm/NOWG

In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer’s Disease (“AD”). SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies. Columbia University Irving Medical Center (“CUIMC”), an “internationally recognized leader” in research and therapeutic development, partnered with Silo to study psychedelics’ ability to improve, slow, or even reverse functional decline and memory loss associated with Alzheimer’s disease. Associate Professor of Clinical Neurobiology, Dr. Christine Ann Denny, helming the research for Silo, explores “the molecular mechanisms underlying learning and memory,” and has co-authored research detailing psychedelic treatment for depression, mechanisms of age-related memory loss, mood improvement and stress reduction. Silo Parma CEO Eric Weisblum expressed encouragement on partnering with Dr. Denny and Columbia University. “To be able to bring hope and possibly a therapeutic to patients suffering from Alzheimer’s disease is an exciting proposition for Silo Pharma.” The Mayo Clinic defines Alzheimer’s Disease as an incurable and progressive “neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die. [AD] is the most common cause of dementia — a continuous decline in thinking, behavioral and social skills that affects a person’s ability to function independently.” The National Institute on Aging (“NIA”), one of the 27 institutes and centers forming The National Institutes of Health (“NIH”), offers the following AD facts:

• Over 6 million Americans, mostly over 65, may have AD-related dementia.
• AD ranks seventh among all leading causes of US deaths and is the most “common cause of dementia among older adults.”
• Early-onset AD affects people between their 30s and mid-60s though represents under 10% of Alzheimer’s patients.
• Behavioral symptoms include sleeplessness, wandering, agitation, anxiety, and aggression.
• Diagnosis includes performing standard medical tests and various brain scans, ascertaining medical history, personality or behavioral changes, current mental health issues and cognitive, memory and self-care abilities.
• AD is degenerative and worsens at different rates among patients, from early mild AD symptoms to complete dependence on caretakers.
• Alzheimer’s Disease International states that the “annual global cost of dementia is now above US$ 1.3 trillion and is expected to rise to US$ 2.8 trillion by 2030.”

Currently, there is no AD cure.  Studies have pointed towards preventative methods, according to the AAFP, “that may affect the incidence of [AD], such as the use of dietary supplements and pharmacologic agents” as well as lifestyle choices and circumstances, including “diet, socioeconomic factors, medical conditions, and environmental exposures,” though these studies have been unable to prove actual causation or efficacy. Drugs used to treat mild to severe AD symptoms include “galantamine, rivastigmine, and donepezil … cholinesterase inhibitors that … may help reduce or control some cognitive and behavioral symptoms.”  Science can’t explain why these drugs work and all lose efficacy over time as AD progresses. Side effects include “nausea, vomiting, diarrhea, decreased appetite, dizziness, headache.” Aducanumab, the only FDA-approved disease-modifying drug for AD treatment, targets “brain lesions associated with Alzheimer’s,” though effectiveness has only been studied on those with early or mild symptoms.  Aducanumab is “administered intravenously (“IV”) via a 45- to 60-minute infusion every 4 weeks” and may “slow the progression of the earliest symptoms…” Side effects can be serious, including “brain inflammation called amyloid-related imaging abnormalities (‘ARIA’), which involves brain bleeding, brain swelling, or a combination of the two.” A peer-reviewed article in Frontiers in Synaptic Neuroscience illustrates the interest in psychedelics by the AD medical community,  particularly “their potential to stimulate neurogenesis [process of generating functional neurons], provoke neuroplastic changes [structural and functional changes to the brain] and reduce neuroinflammation. This inevitably makes them interesting candidates for therapeutics in dementia.” Some important points raised in the article:

• Psychedelics induce brain plasticity and modify connectivity between brain regions and there is considerable anecdotal evidence of cognitive benefits from micro-dosing—a dose that does not cause perceptual change or impair functioning…
• A 2018 uncontrolled, open-label naturalistic trial found increased cognitive fluency, flexibility, and originality amongst the 33 participants at various micro-doses of psilocybin… In general, the medication was well tolerated with no serious adverse events or drop-outs.
• In treatment-resistant depression, 10 mg and 25 mg of psilocybin given 1 week apart  … led to clinical response or remission in 14 participants sustained at assessment 5 weeks later. This effect persisted at 6 months follow up despite no further treatment…
• In AD there is a reduction in global brain glucose metabolism … In the only psilocybin FDG-PET study to date … ingestion of a 15 mg or 20 mg dose increased global brain glucose metabolism by approximately 25% …
• All known genetic and environmental risk factors for AD are associated with increased inflammation … Psychedelics have been shown to have potent anti-inflammatory properties and … may represent a unique anti-inflammatory overwhelmingly targeted to brain tissue …

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science, in the Journal of Psychopharmacology states that “The first RCT [randomized controlled trial] comparing psilocybin to a conventional selective serotonin reuptake inhibitor (‘SSRI’) antidepressant found the former to be as efficient at reducing symptoms of depression, and with fewer side effects … Most researchers now consider classic psychedelics to be non-toxic, that is, they do not damage mammalian organ systems, and as physiologically safe, even in very high doses…” Alongside Silo’s work with Columbia University, they’re also exploring methods for delivering psychedelic therapeutics in extremely targeted doses.  Partnering with the University of Maryland Baltimore, Silo believes central nervous system (“CNS”) homing peptides can deliver a microdose “payload” to inflamed tissue while bypassing healthy organs. A Silo Pharma news release says, “the ability to deliver psilocybin and other psychedelic compounds directly to targeted areas of the body … could be significant by increasing the efficacy of the treatment while reducing the amount of medicine needed.” Silo’s partnership developing Zylo Therapeutics Z-pod technology for sustained transdermal delivery delivers time-released ketamine or psilocybin which will, says Silo CEO Eric Weisblum, “allow [Silo] to explore both the safety and efficacy of our therapeutics while hopefully diminishing the hallucinogenic effects of psychedelics.  We believe that Zylo’s patented technology will allow us to reach potential patients suffering from dysphagia, an inability to swallow affecting those with severe AD. Silo is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease. We eagerly await results from recent research which utilizes cutting-edge psychedelic therapeutics and traditional treatments.” For Silo Pharma’s most recent news, click here. Silo Pharma 560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632 For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• The global indoor farming market projected to grow from $26.5 billion in 2021 to $62 billion by 2030
• Report indicates that United States holds major share in terms of revenue in North America indoor farming market
• Grow Pods offered through ACTX provide a controlled environment, ability to grow year-round

The newest projections for the global indoor farming sector are in, and the numbers bode well for Advanced Container Technologies (OTC: ACTX). ACTX is the exclusive U.S. distributor of Grow Pods, environmentally controlled micro-farms that allow cultivation of ultra-clean crops all year long. “The study undertaken by Astute Analytica foresees a tremendous growth in revenue of the market for the global indoor farming market from US$26.5 billion in 2021 to US$62 billion by 2030,” a recent PR Newswire report states (https://ibn.fm/DUwJn). “The market is anticipated to grow at a CAGR of 10.1% during the forecast period 2022–2030. The article notes that indoor vertical farming is defined as the practice of growing produce stacked one above another in a closed, controlled environment. “Growing crops on vertically mounted shelves significantly reduces the amount of land space needed to grow plants compared to traditional farming methods,” the article observes. “Vertical farms are unique in the sense that some setups do not require soil for plants to grow,” the article continues. “Most are either hydroponic, where vegetables are grown in a nutrient-dense bowl of water, or aeroponic, where the plant roots are systematically sprayed with water and nutrients. Moreover, vertical farms use smart sensors to monitor technical variables including temperature, carbon dioxide, oxygen, lighting, humidity, nutrient concentration, pH, pest control, irrigation and harvesting.” The Astute Analytica report showed that the United States holds the major share in terms of revenue in the North America indoor farming market, with projections to grow with the highest CAGR during the forecast period. “Moreover, developed countries such as U.S. and Canada are the rapid and early adopters of indoor farming technologies,” the article said. “Furthermore, based on the growing system, the hydroponics segment holds the highest share in the North America indoor farming market in 2021 as it reduces the amount of space and water required for cultivation.” Offering the ability to grow high-quality crops anywhere, the Grow Pods offered through Advanced Container Technologies provide a controlled environment and the ability to grow year-round. The micro-farms also enable cultivation in a smaller footprint using less resources — huge advantages in a world where environmental and sustainability concerns are top priorities for consumers. In November 2020, ACTX announced that it had entered into an agreement with Grow Pods manufacturer GP Solutions for the exclusive right to market, sell and distribute GP products in the United States and its territories (https://ibn.fm/AP3PQ). At the time of the agreement, GP Solutions president George Natzic stated that “we are very enthusiastic about this agreement and look forward to letting the experts at ACT handle sales and marketing while we focus on manufacturing new products, and expanding into new industries and territories.” For more information, visit the company’s website at www.AdvancedContainerTechnologies.com. NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://ibn.fm/ACTX